Bristol Myers adds to neoadjuvant win for Opdivo in lung cancer, escalating early cancer showdown with Merck

Bristol Myers Squibb and Merck are locked in a heated race to bring their blockbuster PD-(L)1 drugs into early cancer patients as part of potentially curative combinations. The approvals have been coming fast and heavy, and Bristol Myers keeps adding to its case for a big-time FDA nod in lung cancer.